Ozkan Elgin, Soydal Cigdem, Araz Mine, Kir Kemal Metin, Ibis Erkan
Department of Nuclear Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey.
Nucl Med Commun. 2012 Apr;33(4):395-402. doi: 10.1097/MNM.0b013e32834f7dbe.
In this study we aimed to define the success of fluorine-18 (18F) fluorodeoxyglucose (FDG) PET/computed tomography (PET/CT) in detecting recurrent disease in our patient group with colorectal cancer (CRC) and elevated carcinoembryonic antigen (CEA) levels.
Patients who had a previous diagnosis of CRC were searched retrospectively in our PET center database. Seventy-six 18F-FDG PET/CT studies between October 2006 and December 2010 of 69 patients (25 women, 44 men; mean age: 61.61 ± 4.1 years) with elevated CEA levels were evaluated. 18F-FDG PET/CT findings and concurrent abdominopelvic contrast-enhanced computed tomography (ceCT) findings were compared with histopathological findings and/or clinical follow-up data as the 'gold standard'.
In the patient-based analysis, the sensitivity and specificity of 18F-FDG PET/CT in the detection of disease recurrence were calculated as 97 and 61%, respectively. A statistically significant difference was found in frequencies of positive and negative 18F-FDG PET/CT findings between patients with or without recurrent disease by gold standard (P<0.05). There was no correlation between patients' serum CEA levels and lesions' maximum standardized uptake values (P=0.85). The sensitivity and specificity of ceCT were computed as 51 and 60%, respectively. In the evaluation of separate patient groups, although the sensitivity and specificity of 18F-FDG PET/CT were calculated as 100 and 60% in the group whose CEA level elevation was less than two-fold (5-9.9 ng/ml), these were 100 and 75% in the group with CEA elevation less than three-fold (10-14.9 ng/ml) and 95 and 62% in the group with elevation more than three-fold (≥ 15 ng/ml). The sensitivity and specificity of 18F-FDG PET/CT were computed as 98 and 85% in the lesion-based evaluation. The sensitivity and specificity of ceCT were 73 and 86%, respectively.
18F-FDG PET/CT is a safe imaging method that can be used in the determination of CRC recurrence in patients with elevated CEA levels, regardless of the CEA level.
在本研究中,我们旨在确定氟-18(18F)氟脱氧葡萄糖(FDG)PET/计算机断层扫描(PET/CT)在检测我们的结直肠癌(CRC)患者组中复发疾病及癌胚抗原(CEA)水平升高方面的成功率。
在我们的PET中心数据库中对先前诊断为CRC的患者进行回顾性检索。评估了2006年10月至2010年12月期间69例(25例女性,44例男性;平均年龄:61.61±4.1岁)CEA水平升高患者的76次18F-FDG PET/CT检查。将18F-FDG PET/CT检查结果和同期腹盆腔增强计算机断层扫描(ceCT)结果与作为“金标准”的组织病理学结果和/或临床随访数据进行比较。
在基于患者的分析中,18F-FDG PET/CT检测疾病复发的敏感性和特异性分别计算为97%和61%。通过金标准判断,有或无复发疾病的患者之间18F-FDG PET/CT阳性和阴性结果的频率存在统计学显著差异(P<0.05)。患者血清CEA水平与病变的最大标准化摄取值之间无相关性(P=0.85)。ceCT的敏感性和特异性分别计算为51%和60%。在对不同患者组的评估中,尽管在CEA水平升高小于两倍(5 - 9.9 ng/ml)的组中,18F-FDG PET/CT的敏感性和特异性计算为100%和60%,但在CEA升高小于三倍(10 - 14.9 ng/ml)的组中分别为100%和75%,在升高超过三倍(≥15 ng/ml)的组中分别为95%和62%。在基于病变的评估中,18F-FDG PET/CT的敏感性和特异性分别计算为98%和85%。ceCT的敏感性和特异性分别为73%和86%。
18F-FDG PET/CT是一种安全的成像方法,可用于确定CEA水平升高的CRC患者的复发情况,无论CEA水平如何。